RCEL Earnings Date: Nov 5, 2026 (Estimated) — Avita Medical Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is RCEL's next earnings date?
Avita Medical Inc. (RCEL) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.24 on revenue of $22.4M.
How did RCEL do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Avita Medical Inc. posted EPS of -$0.25 versus the -$0.29 estimate, a beat of 32.4%. Revenue was $21.7M against a $20.3M estimate. The stock's 1-day post-earnings move was +63.6%.
How much does RCEL stock move after earnings?
RCEL beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 15.0% (up or down) in the day after earnings.
About Avita Medical Inc.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.29 | -0.25 | +32.43% | $21.7M | ✅ Beat | +63.58% | +68.63% | +135.79% |
| 2026-05-14 | Q1 2026 | -0.38 | -0.35 | +7.89% | $19.3M | ✅ Beat | +4.59% | +2.75% | -9.86% |
| 2026-02-12 | Q4 2025 | -0.47 | -0.38 | +19.15% | $17.6M | ✅ Beat | +11.83% | +28.76% | +24.19% |
| 2025-11-06 | Q3 2025 | -0.44 | -0.46 | -4.55% | $16.9M | ❌ Miss | +10.88% | +10.00% | +1.47% |
| 2025-02-13 | Q4 2024 | -0.74 | -0.44 | +40.54% | $18.4M | ✅ Beat | +20.39% | +11.05% | +2.85% |
| 2024-11-07 | Q3 2024 | -0.44 | -0.62 | -40.91% | $19.4M | ❌ Miss | -3.63% | +1.45% | +10.48% |
| 2024-05-13 | Q1 2024 | -0.45 | -0.73 | -62.22% | $11.1M | ❌ Miss | +4.43% | -2.16% | +5.99% |
| 2024-02-22 | Q4 2023 | -0.37 | -0.28 | +24.32% | $14.2M | ✅ Beat | +0.53% | +6.58% | -7.76% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $19.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Recell System | 98.9% | $19.0M | +13.3% | — | $17.7M | $16.8M | $15.4M |
| Lease Revenue | 1.1% | $213K | +10.9% | $194K | $189K | $192K | $165K |
By region
Q2 FY26 · $21.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 96.5% | $20.8M | +16.5% | $18.0M | $17.8M | $17.9M | $16.0M |
| JAPAN | 1.8% | $387K | -9.4% | $193K | $634K | $427K | $605K |
| AUSTRALIA | 0.9% | $194K | +385.0% | $180K | $40K | $40K | $80K |
| European Union | 0.8% | $182K | +271.4% | $1K | $49K | $49K | $49K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.